Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects.
- 1 November 1987
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 76 (5), 1043-1052
- https://doi.org/10.1161/01.cir.76.5.1043
Abstract
In patients with pulmonary hypertension associated with congenital heart defects, ultrastructural abnormalities are observed in endothelial cells, which suggest heightened metabolic function. If endothelial production of the von Willebrand factor (vWF) is increased, this may be associated with abnormal interactions with platelets leading to worsening of the pulmonary hypertension. We therefore evaluated vWF in 30 patients with pulmonary hypertension (25 with congenital heart defects) and in 30 individuals with normal pulmonary arterial pressure (12 with congenital heart defects). We measured the antigenic (vWF: Ag) and biologic (VWF: rist) activity of vWF in plasma and assessed endothelial vWF: Ag directly by an immunoperoxidase stain applied to lung biopsy tissue. Because of considerable variance and small size, the group of five patients with pulmonary hypertension and without congenital heart defects were excluded from statistical analyses. Patients with pulmonary hypertension and congenital heart defects had significant higher vWF: Ag levels than individuals with normal pulmonary arterial pressure without congenital heart defects (p less than .05), whereas values in those with normal pressure and congenital heart defects were intermediate. In lung biopsy tissue available from 29 patients in this study and from 11 others we previously reported, immunostain of pulmonary arterial endothelium for vWF was intense (suggesting increased production) in 29 of 32 with pulmonary hypertension and congenital heart defects and in only one of eight with normal pulmonary arterial pressure and congenital heart defects (p less than .01). Only three patients with congenital heart defects and pulmonary hypertension and increased vWF: Ag, however, had increased vWF: rist. Compatible with this discrepancy was a loss of vWF high-molecular weight forms as determined by both crossed immunoelectrophoresis and multimeric analysis. Our results suggest that increased vWF in most patients with congenital heart defects and pulmonary hypertension is associated with increased production of a biologically deficient molecule lacking high-molecular weight forms.This publication has 23 references indexed in Scilit:
- Abnormal VIII: von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndromeBlood, 1984
- Hypoxia alters blood coagulation during acute decompression in humansJournal of Applied Physiology, 1984
- Altered Factor VIII in Acute Respiratory FailureNew England Journal of Medicine, 1982
- Alterations of Factor VIII von Willebrand Factor in Clinical Conditions Associated with an Increase in its Plasma ConcentrationBritish Journal of Haematology, 1981
- The factor VIII complex: structure and functionBlood, 1981
- The complex multimeric composition of factor VIII/von Willebrand factorBlood, 1981
- Thromboxane synthesis and platelet secretion during cardiopulmonary bypass with bubble oxygenatorThe Journal of Thoracic and Cardiovascular Surgery, 1980
- Fluorescent substrate assay for antithrombin IIIThrombosis Research, 1978
- Effect of exercise on F VIII-complex: Proportional increase of ristocetin cofactor (von Willebrand factor) and F VIII-AGN, but disproportional increase of F VIII-AHFThrombosis Research, 1977
- The Partial Thromboplastin Time with Kaolin: A Simple Screening Test for First Stage Plasma Clotting Factor DeficienciesAmerican Journal of Clinical Pathology, 1961